



# ***Pathology***

***Subject :***

***Lec no :*** lec-26-

***Done By :*** Hala AL Beshtawe

وَقُلْ رَبِّ زِدْنِي عِلْمًا


## 3. Altered cellular metabolism

### AUTOPHAGY:

- A state of severe nutrient deficiency in which cells arrest their growth and cannibalize their own organelles, proteins, and membranes (into lysosomes) as carbon sources for energy production.
- Cancer cells may accumulate mutations avoiding autophagy OR alter the process making it inefficient.

**Result: Prolonged cell life!**,

→ Cancer cells aim to avoid autophagy



# 4- Evasion of apoptosis:


## BCL-2 Family:

BAX, BAK : Pro-apoptotic

BCL-2, BCL-XL, MCL1: Anti-apoptotic

**BH3-only proteins** regulate the balance

- Cancer cells are subject to several intrinsic stresses that can initiate apoptosis, particularly DNA damage.



- Tumor cells frequently contain mutations in genes that regulate apoptosis, making the cells **resistant to cell death**.

---

## Apoptosis:

Extrinsic pathway: - Some tumors have **↓ levels of CD95** → ↓ **Apoptosis**

## Intrinsic pathway (mitochondrial pathway):

- ① **loss of p53 function**, either by way of **TP53 mutations** <sup>(A)</sup> or **overexpression MDM2** <sup>(B)</sup>.
- ② **overexpression of anti-apoptotic members of the BCL2** family, which protect cells from the action of the pro-apoptotic members of the BCL2 family.

\* الخلية السرطانية لا تدخل في مرحلة الشيخوخة وذلك بسبب احتوائها على البروتين Telomerase

## 5. Limitless replicative potential (immortality):

- Most normal cells have a capacity of at most 70 doublings. Thereafter, the cells lose the ability to divide and enter replicative senescence due to the progressive shortening of telomeres at the ends of chromosomes.

**Telomeres** Are specialized structures at the end of chromosomes that are shortened after each division and may play a role in determining the life of individual cells.

- Shortening is prevented by **TELOMERASE** (Active in stem cells, not in somatic cells).
- Tumor cells, unlike normal cells, are capable of limitless replication.
- In many cancers, telomerase is reactivated.

Formation of blood vessels → nutrient  
→ O<sub>2</sub>

## 6- Sustained Angiogenesis :

- Tumors remain small or in situ (< 1-2 mm, Diameter) **without angiogenesis.** → بقى كحجم اوليا ال Cancer المتغير

Importance of angiogenesis

① - Supplies needed nutrients and oxygen.

② - Newly formed endothelial cells stimulate the growth of adjacent tumor cells by secreting growth factors. → Tumor growth تحفيز نمو الخلايا السرطانية تحفيز نمو الخلايا السرطانية growth تحفيز نمو الخلايا السرطانية


-The resulting tumor vasculature is effective at delivering nutrients and removing wastes, **it is not entirely normal; the vessels are leaky and dilated.**

\* In Cancer

the Angiogenic factors must be more than Angiogenic inhibitors

-The molecular basis of the angiogenic switch involves increased production of angiogenic factors and/ or loss of angiogenic inhibitors.

**Angiogenesis  $\approx$  Antiangiogenesis**  
**Angiogenic Switch**



- These factors may be produced by the tumor cells or by inflammatory cells (e.g., macrophages) or resident stromal cells (e.g. fibroblasts).

# Angiogenic factors:

vascular endothelial cell formation ← (VEGF) <sup>vascular endothelial growth factor</sup> ← Hypoxia <sup>نقص الأكسجين</sup> ← HIF-1α <sup>\* يعزز هذا الـ</sup>

① - Controlled by HYPOXIA which induces angiogenic factors by tumor cells → Hypoxia-Inducible Factor (HIF-1α) → VEGF → stimulates the proliferation of endothelial cells and guides the growth of new vessels toward the tumor.

② - Gain-of-function mutations in RAS or MYC upregulate the production of VEGF: ↑ VEGF

③ - Proteases from tumor or stroma can release the basic angiogenic FGF stored in the ECM



# ❖ Anti- angiogenesis:

1. **Thrombospondin1**(TSP-1) induced by P53

- Thus, loss of p53 in tumor cells provides a more permissive environment for angiogenesis

2. <sup>von hippel- lindau</sup> **VHL** protein destroys HIF-1  $\alpha$   $\rightarrow$  No VEGF

- Germline mutation of VHL  $\rightarrow$  von Hippel-Lindau Syndrome  $\rightarrow$  hereditary renal CA, CNS hemangiomas.

يكون تكوّن Angiogenesis في حالات ال Cancer كثيره

3. Angiogenesis inhibitors:

Angiostatin, Endostatin, Vasculostatin from stromal cells in ECM.

$\uparrow$  vascular density = Poor prognosis

hall marks of Cancer

## 7- Ability to invade & metastasize:

the most important factor to differentiate between benign & malignant tumor is invasion & metastasize


-Tumors may generate clones and accumulate mutations, leading increased rate of growth, Invasion, Metastases ...

### Metastasis occurs in two phases:

**1- Invasion of extracellular matrix** → like basement membrane  
- Composed of collagens, glycoproteins & proteoglycans.

### 2- Vascular dissemination and homing of tumor cells

تجدد مکانی اگر چه از Primary site of origin



اول خطوات كيف tumor cells تهاجم ECM  
**1- Mechanism Of Invasion Of ECM:**

**1- Loosening of intercellular connections between tumor cells and Detachment:**

① - Inactivation of E-Cadherin OR activation of  $\beta$  catenin → detachment of cells.   
 هكذا تصبح الخلية منفصلة


منه الحركة في الخطوة التالية هي

**2- Degradation of ECM by proteases:**


e.g. Matrix Metalloproteinase (MMPs), Cathepsin D, Type IV collagenase  
 (enzymes)   
 (تأكل)   
 degradation of the ECM

Result of digestion of ECM → Cleavage products have chemotactic activity for more tumor cells

تجذب (ECM) يخلق (tumor cells) تهاجم في تهاجم من المنطقة



tumor cells تربط ← Cadherins  
 بهن



invasion يرتبط و حرم 8- بتلا

3- Attachment of tumor cells to matrix components

4- Migration of tumor cells (Locomotion):


- Propelling tumor cells through the degraded basement membranes and zones of matrix

- Such movement seems to be directed by



- Tumor-derived cytokines

- Motility factor from Stromal cell



الانتشار عن طريق الدم  
Blood vessels

## 2- Vascular dissemination:

### 1- Invasion of the circulation:

Adhesion to endothelium → retraction of endothelium → vessel


تفتح (space) لادخول الخلية

### 2- Attack by NK cells, some escape by formation of a thrombus/embolus

\* Some tumors escape the immunity through thrombus & embolus

### 3- Escape from circulation:

Adhesion to endothelium → retraction of endothelium → escape to tissue



کیسے محدود ہیں - مشترک نوعیت کے Cancer

# What influences site of metastases ?

follow

- Anatomical Location and vascular drainage of the primary tumor → the Cancer in the GI occurs mainly in the liver because most of the venous drainage in the GI goes to the liver
- Complimentary adhesion molecule between tumor cells & target organs
- Chemoattractants liberated by target organs
- Protease inhibitors present in certain tissues

## EXAMPLES OF TROPISM (HOMING) → Cancers doesn't follow the anatomical location

Complementary adhesion molecule → مکملی جاذبہ جزیئہ

chemo attraction → کیمو جاذبہ

① Lung Carcinoma → Adrenals & Brain

② Neuroblastoma → Liver & Bone

لا بڑے قسم (metastatic tumors) کے لیے مخصوص

- Less common sites of metastases: muscle, skin, thyroid, heart ...etc.

- Spleen & Cartilage are almost never involved by metastatic tumors.

# 8. Evasion of Immune Surveillance

## TUMOR IMMUNITY: Host Defense Against Tumors:

- Normal immunity present to protect against the development of tumors
- Tumors have ANTIGENS counteracted by ANTIBODIES in the body

**Evidence?** *عندما نتحقق* *البيانات الكافية* *T cells* *specific antibodies* *الدليل على ذلك وجود* *reactions against antigens on the surface of the tumor cells* *جزي (antibodies)* *لأن \**

- The direct demonstration of tumor-specific T cells and antibodies in patients
- When there is no immunity (immunosuppressed patients) → More Cancers
- Patients with congenital immune deficiency have ↑ risk of cancer

*متى*

# Host defenses

\* أنواع الخلايا أو المواد التي تقوم بعمل استجابة مناعية ضد السرطانات

- ① - <sup>T lymphocytes</sup> CTLs (CD8+ T-Cells)
- ② - NK cells
- ③ - T helper cells
- ④ - Macrophages
- ⑤ - Humoral (Antibodies) <sup>lymphocytes type-B تتعرف ال</sup>



# Types of tumor antigens:

## 1- Products of mutant oncogenes & tumor suppressor genes

So the body can recognize them as something abnormal  
 ← abnormal product of mutation in RAS oncogene or tumor suppressor gene

## 2- Mutant proteins in chemical and radiation-induced tumors






## 3- Overexpressed or aberrantly expressed cellular proteins.

e.g.: Tyrosinase in melanoma

## 4- Tumor AG produced by oncogenic viruses in HPV (E6, E7)

## 5- Oncofetal AG: CEA and $\alpha$ fetoprotein

## 6- Several mucins MUC-1


Normal host cell displaying multiple MHC-associated self antigens		EXAMPLES
Tumor cells expressing different types of tumor antigens		Oncogene products: mutated RAS, Bcr/Abl fusion proteins Tumor suppressor gene products: mutated p53 protein
		Various mutant proteins in carcinogen, or radiation, induced animal tumors; various mutated proteins in melanomas
		Overexpressed: tyrosinase, gp100, MART in melanomas Aberrantly expressed: cancer-testis antigens (MAGE, BAGE)
		Human papilloma virus E6, E7 proteins in cervical carcinoma; EBNA proteins in EBV induced lymphoma

reaction against them ←

# How do tumor cells escape immune surveillance?

-In immunocompetent patients, tumors may avoid the immune system by :

- ❖ Selective outgrowth of antigen-**negative** variants. *(antigene) Growth لا يواجب لا تختبره مع اب*
- ❖ **Loss or reduced expression** of MHC molecules on tumor cell surface
- ❖ **Immunosuppression** mediated by expression of certain factors (e.g. Pd-1 ligands) by the tumor cells.
- ❖ **Antigen masking**
- ❖ **Downregulation of co-stimulatory molecules** (sensitization of T- cells requires costimulatory molecules).



# Genomic Instability as an Enabler of Malignancy:

---

- Individuals born with inherited **defects in DNA repair genes** are at greatly **increased risk for the development of cancer.**

- Includes:

- **Mismatch repair**
- **Nucleotide excision repair**
- **Recombination repair**

# 1- Mismatch repair genes:

- These repair errors in the pairing of nucleotides during cell division (Spell Checkers) e.g. G+T instead of A+T.
- Defective in (HNPCC – Hereditary Nonpolyposis Colonic Ca. syndrome):
  - This syndrome accounts for 2-4% of all colonic ca, AD.
- Carcinomas of the colon affecting predominantly the cecum and proximal colon (right colon)
- A characteristic finding in the genome of patients with mismatch repair defects is microsatellite instability (MSI).

## 2- Nucleotide excision repair genes

---

- **Defective in Xeroderma Pigmentosum:**

- Autosomal recessive disorder.

- Increased risk for cancers arising in sun-exposed skin.

- UV rays in sunlight cause cross-linking of pyrimidine residues. The nucleotide excision repair system repairs such DNA damage.

- Several proteins are involved in nucleotide excision repair, and the inherited loss of any one of these can give rise to xeroderma pigmentosum.

### 3. DNA Repair by Homologous Recombination:

---

- A group of AR disorders comprising **Bloom syndrome, ataxia-telangiectasia, and Fanconi anemia** is characterized by hypersensitivity to DNA-damaging agents.



These have defects in DNA Repair by Homologous Recombination

## BRCA-1 & BRCA-2: → mutated in Familial Cancer & not Sporadic =

- Cells with a defective version of these genes develop chromosomal breaks and severe aneuploidy. Both genes seem to function, at least in part, in the **homologous recombination DNA repair pathway**

(BRCA2) & (BRCA1) → جين مرتبط

- **50% of familial breast cancers & ovarian CA**

- Rarely inactivated in sporadic cases.